Dermatomyositis causes muscle weakness and a distinctive skin rash, often appearing as purple or red patches on the eyelids, knuckles, and other areas. It affects about 10 people per million each year. Most treatment involves corticosteroids and immunosuppressants that calm the immune attack on muscle and skin.
What's actually going on in research
Trials are testing JAK inhibitors that may control skin disease better than older drugs, rituximab for muscle inflammation, and intravenous immunoglobulin for people who don't respond to standard treatment. Researchers are also studying the role of specific autoantibodies that predict disease patterns and treatment response.
JAK inhibitors
Tofacitinib and other JAK inhibitors are being tested for dermatomyositis skin disease, which often persists despite treatment. Early studies suggest they may clear rashes more effectively than current options.
Targeted immunotherapy
Rituximab and other drugs that target specific immune cells are being studied to see if they work better with fewer steroid side effects. Some trials test these drugs early in disease, before muscle damage becomes permanent.
What to know before you search
Eligibility typically depends on disease activity, specific antibody type, prior treatments, and whether skin or muscle symptoms are more prominent.
What types of trials are currently open
- Treatment trials — Testing new immunosuppressants or combinations to control muscle and skin inflammation while reducing steroid doses.
- Skin-focused trials — Studies of drugs specifically targeting the rash, which can be disfiguring and doesn't always respond to treatments that help the muscles.
- Biomarker studies — Following people with dermatomyositis to see how autoantibodies and other markers predict disease course and treatment response.
- Intravenous immunoglobulin trials — Testing IVIG for people whose disease doesn't respond to standard drugs or who can't tolerate high-dose steroids.
- Natural history studies — Tracking how dermatomyositis progresses over time, including cancer risk and long-term muscle function.
Recently added Dermatomyositis trials
Take an experimental immune therapy for autoimmune disease
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.
Receive an infusion of engineered immune cells for muscle inflammation
This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).
Find Dermatomyositis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.